Comparing the use of aggregate data and various methods of integrating individual patient data to network meta-analysis and its application to first-line ART

Kanters, Steve; Karim, Mohammad Ehsanul; Thorlund, Kristian; Anis, Aslam H.; Zoratti, Michael; Bansback, Nick

doi:10.1186/s12874-021-01254-5

Table 1 Comparison of model selection and fit of all models considered in the analysis for viral suppression at 48 weeks as an outcome

From: Comparing the use of aggregate data and various methods of integrating individual patient data to network meta-analysis and its application to first-line ART

Analyses	Model	DIC	pD	Deviance	Between study heterogeneity	prop3	prop4
AgD NMA – Unadjusted	Fixed	186.69	68.38	118.31	0.07 (0.003, 0.199)	2/116	2/116
AgD NMA meta-regression – CD4	Fixed	187.26	69.25	118.01	0.082 (0.006, 0.211)	2/116	2/116
AgD NMA meta-regression – HIV RNA	Fixed	188.79	69.38	119.41	0.07 (0.005, 0.194)	2/116	2/116
AgD NMA meta-regression – Male	Fixed	188.98	69.42	119.56	0.07 (0.003, 0.195)	2/116	2/116
Two-stage AgD NMA – CD4 + HIV RNA + Male	Fixed	189.14	68.37	120.77	0.072 (0.003, 0.204)	2/116	2/116
Two-stage AgD NMA – CD4 + Male	Fixed	188.21	68.38	119.83	0.076 (0.003, 0.208)	2/116	2/116
Two-stage AgD NMA – CD4 + HIV RNA	Fixed	193.10	68.42	124.68	0.088 (0.005, 0.228)	3/116	2/116
Two-stage AgD NMA – HIV RNA + Male	Fixed	190.15	68.44	121.71	0.078 (0.005, 0.215)	2/116	2/116
Two-stage AgD NMA – HIV RNA	Fixed	191.23	67.67	123.56	0.087 (0.005, 0.225)	3/116	2/116
Two-stage AgD NMA – CD4	Fixed	189.06	67.70	121.36	0.082 (0.005, 0.222)	2/116	2/116
Two-stage AgD NMA – Male	Random	205.19	82.51	122.68	0.167 (0.017, 0.306)	4/116	3/116
One-stage IPD-AgD NMA – unadjusted	Fixed	185.11	68.45	116.66	0.072 (0.003, 0.2)	2/116	2/116
One-stage IPD-AgD NMA – CD4 + HIV RNA + Male	Fixed	188.65	71.41	117.24	0.066 (0.003, 0.204)	2/116	2/116
One-stage IPD-AgD NMA – CD4 + Male	Fixed	188.35	70.21	118.14	0.074 (0.002, 0.206)	2/116	2/116
One-stage IPD-AgD NMA – CD4 + HIV RNA	Fixed	187.19	70.54	116.65	0.073 (0.004, 0.204)	2/116	2/116
One-stage IPD-AgD NMA – HIV RNA + Male	Fixed	188.90	70.58	118.32	0.074 (0.004, 0.207)	2/116	2/116
One-stage IPD-AgD NMA – CD4	Fixed	186.82	69.31	117.51	0.067 (0.001, 0.206)	2/116	2/116
One-stage IPD-AgD NMA – HIV RNA	Fixed	187.76	69.36	118.4	0.074 (0.003, 0.203)	2/116	2/116
One-stage IPD-AgD NMA – Male	Fixed	186.40	69.48	116.92	0.068 (0.004, 0.199)	2/116	2/116
Two-stage empirical-priors approach– CD4 + HIV RNA + Male	Fixed	198.56	77.47	121.09	0.104 (0.012, 0.244)	2/116	2/116
Two-stage empirical-priors – CD4 + Male	Fixed	197.69	74.18	123.51	0.108 (0.006, 0.253)	2/116	2/116
Two-stage empirical-priors – CD4 + HIV RNA	Fixed	192.22	74.75	117.47	0.071 (0.003, 0.221)	2/116	2/116
Two-stage empirical-priors – HIV RNA + Male	Fixed	195.30	74.40	120.90	0.091 (0.004, 0.23)	2/116	2/116
Two-stage empirical-priors – CD4	Fixed	191.28	71.49	119.79	0.082 (0.008, 0.215)	2/116	2/116
Two-stage empirical-priors – HIV RNA	Fixed	193.05	71.16	121.89	0.09 (0.004, 0.228)	3/116	2/116
Two-stage empirical-priors – Male	Fixed	188.59	71.81	116.78	0.075 (0.004, 0.208)	2/116	2/116
HMR IPD-AgD NMA – CD4	Fixed	185.25	70.07	115.18	0.061 (0.005, 0.181)	2/116	2/116
HMR IPD-AgD NMA – HIV RNA	Fixed	187.21	70.45	116.76	0.066 (0.001, 0.192)	2/116	2/116
HMR IPD-AgD NMA – Male	Fixed	186.34	70.44	115.90	0.072 (0.003, 0.197)	2/116	2/116

AgD Aggregate data, IPD Individual patient data, NMA Network meta-analysis, DIC Deviance information criterion, pD Effective number of parameters, prop3 Proportion of observations above deviance² + leverage = 3, prop4 Proportion of observations above deviance² + leverage = 4. Between-study heterogeneity obtained through the random-effects model, not the fixed-effect model if it was selected

Back to article page

ISSN: 1471-2288

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Medical Research Methodology

Contact us